RE:RE:RE:NSCLC From the Feb 13, 2015 news release - "
Theralase’s Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug"
"Photofrin® has been documented to induce skin sensitivity in patient’s treated with the PDC to sunlight or bright lights after administration. Patients who receive Photofrin® will be photosensitive and must strictly avoid exposure of skin and eyes to direct sunlight or bright indoor light (i.e.: examination lamps, dental lamps, operating room lamps, unshaded light bulbs at close proximity, etc.) for at least 30 days post treatment. Some patients may remain photosensitive for up to 90 days or more. The photosensitivity is due to residual traces of the drug, which will be present in all parts of the skin. This necessitates the patient to stay indoors after treatment to prevent potential skin damage.
"Theralase employed a mouse model and Inductively Coupled Plasma Mass Spectrometry (“ICP-MS”) to measure the levels of TLD-1433 in skin following systemic administration (worst-case scenario). Previously published mathematical models were then used to compare the sensitivity of skin containing TLD-1433 to Photofrin®. TLD-1433 produced 10,000,000 times less Reactive Oxygen Species (“ROS”) in the skin than Photofrin®; therefore, providing a much higher safety margin to light sensitivity than Photofrin® allowing patients the opportunity post treatment to enter direct sunlight within days and not months.
This latest research adds more support to the high safety profile of the lead drug candidate TLD-1433 and its ability to minimize one of the reported side effects of PDT by a FDA approved PDC."
enriquesuave wrote: From what we know so far, much smaller amounts of Rutherin are needed, than say Photofrin IMO in order to achieve high efficacy. As well Rutherin can be activated by X-rays as well. So overall with a smaller amount of drug in the system, I would expect less light sensitivity with rest of body and more so for a lesser amount of time. Just IMHO